Description

LFM-A13 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC50s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research[1][3][4]–20°C, 3 years; 4°C, 2 years (Powder)-Applications-Cancer-Kinase/protease-Formula-C11H8Br2N2O2-Citation–References-[1]Mahajan S, et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton’s tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]. J Biol Chem. 1999 Apr 2;274(14):9587-99.|[2] van den Akker E, et al. The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity. Biol Chem. 2004 May;385(5):409-13.|[3]Uckun FM, et al. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). Bioorg Med Chem. 2007 Jan 15;15(2):800-14.|[4]Sahin K, et al. LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice. Invest New Drugs. 2018 Jun;36(3):388-395. -CASNumber-62004-35-7-MolecularWeight-360.00-Compound Purity–SMILES-C/C(O)=C(C#N)/C(NC1=CC(Br)=CC=C1Br)=O-Research_Area-Cancer-Solubility-10 mM in DMSO-Target-Btk;JAK;Polo-like Kinase (PLK)-Isoform-PLK1;PLK3-Pathway-Cell Cycle/DNA Damage;Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt-MCE Product type-Biochemical Assay Reagents